VivoSeq
Oncology

Primary Central Nervous System Lymphoma

9

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Primary Central Nervous System Lymphoma is an early-stage landscape with 9 programs across 7 companies. The most active players are Astellas, Teva, Alnylam Pharmaceuticals. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 3Roche logo

Roche

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

8 of 11 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody327%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

3

clinical trials

Active, not recruiting1 · 33%
Recruiting1 · 33%
Suspended1 · 33%

Clinical Trials

Trial Activity

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02203526·68 enrolled
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
Recruiting·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 3·NCT07104032·132 enrolled
A Phase 1b Study of Glofitamab in CNS Lymphoma
Suspended·CCity of Hope Medical Center·Phase 1·NCT06922604·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)